Biophytis SA
About Biophytis SA
Biophytis SA is a France-based clinical-stage biotechnology company specializing in the development of drug candidates to treat ageing diseases, including sarcopenia and Age-Related Macular Degeneration (ARMD). Its lead programs include Sarconeos (BIO101) for muscle wasting conditions and Macuneos (BIO201). The company is advancing clinical trials such as the Phase 2 OBA study for muscle wasting associated with obesity and maintains operations focused on clinical and regulatory development.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Announced €1.0M bond facility with Hexagon Capital Fund including initial €100k subscription.
- Secured ANVISA approval to begin Phase 2 OBA clinical trial for obesity in Brazil.
- Strengthened cash position to €3.0M extending runway into Q1 2027.
- Advancing Phase 3 sarcopenia trial strategy for BIO101 in Europe and Asia.
- Established Hong Kong joint venture Biophytis Biopharmaceutical Holding LTD.
Ask StreetZero about Biophytis SA
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account